New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced three data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), occurring July 9–12, 2021. The study evaluates the Accelerate Pheno system's impact on bloodstream infection treatment across multiple hospitals. Key findings include a statistically significant reduction in 30-day mortality (6.0% in AXDX vs. 15.9% in SOC) for patients receiving ineffective empirical treatment. The presentations highlight improved microbiology test turnaround times and antimicrobial use.
- Significant reduction in 30-day mortality observed in patients using the Accelerate Pheno system (6.0% vs. 15.9% in SOC).
- Improved microbiology test turnaround times noted in clinical settings.
- None.
TUCSON, Ariz., June 30, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021. The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections.
The ePoster presentations are from real-world clinical use of the Accelerate Pheno system in diverse health systems and include endpoints for microbiology test turnaround time, antimicrobial use, and a subgroup analysis that measured 30-day mortality. The data further highlight the clinical benefits of using the Accelerate Pheno system, with significant improvements in multiple endpoints, including a statistically significant reduction in 30-day mortality in the Accelerate Pheno arm (AXDX) versus standard of care testing arm (SOC) in a subset of patients on ineffective empirical antibiotic treatment (
The Company's presentations, which are available now on the ECCMID 2021 website, include:
Antimicrobial Use in Patients with Bloodstream Infections from 4 Hospitals in the IOAS Study: A Quasi-Experimental Multicenter Study of the Accelerate PhenoTest® BC Kit
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 661
ePoster Session: S147-3c
Evaluating the Impact of the Accelerate PhenoTest® BC Kit (AXDX) on Patients with Bloodstream Infections Receiving Ineffective Empirical Antibiotic Treatment: IOAS Study Experience of 4 Hospitals
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 664
ePoster Session: S138-2b
Impact of the Accelerate PhenoTest® BC Kit on Time to Results for Pathogens from Bloodstream Infections: IOAS (Improving Outcomes and Antibiotic Stewardship) Study Experience of 4 Hospitals
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 758
ePoster Session: S147-3c
To view the presentations or more information, visit the ECCMID 2021 website at: https://www.eccmid.org/.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Such forward looking statements include any implication that the results of the new landmark study will be realized at other customers using the Accelerate Pheno system. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 2, 2021, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions, and regulatory approvals. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-accelerate-pheno-landmark-study-validates-important-clinical-benefits-to-be-presented-at-eccmid-2021-301323237.html
SOURCE Accelerate Diagnostics, Inc.
FAQ
What are the key findings from the Accelerate Diagnostics study at ECCMID 2021?
When is the ECCMID 2021 conference where AXDX is presenting?
What is the significance of the Accelerate Pheno system in treating bloodstream infections?
Where can I find the presentations from Accelerate Diagnostics at ECCMID 2021?
What does AXDX stand for?
